0 Maoni
0 Shiriki
24 Mitazamo
0 Hakiki
Tafuta
Gundua watu wapya, unda miunganisho mipya na upate marafiki wapya
-
Tafadhali ingia kwenye akaunti ili kupenda, kushiriki na kutoa maoni!
-
Liposomal Drugs Market Shows Strong Potential with Enhanced Drug Delivery and Targeted Therapies"Future of Executive Summary Liposomal Drugs Market: Size and Share Dynamics CAGR Value Global liposomal drugs market size was valued at USD 5.31 billion in 2024 and is projected to reach USD 10.21 billion by 2032, with a CAGR of 8.50% during the forecast period of 2025 to 2032. The Liposomal Drugs business document lists and studies the leading competitors and also provides the...0 Maoni 0 Shiriki 125 Mitazamo 0 Hakiki
-
Oral HER Pathway Targeted Drugs Market Strengthens with Breakthrough Oncology Therapies"Detailed Analysis of Executive Summary Oral HER Pathway Targeted Drugs Market Size and Share CAGR Value The global oral HER pathway targeted drugs market size was valued at USD 6.24 billion in 2025 and is expected to reach USD 15.01 billion by 2033, at a CAGR of 11.60% during the forecast period The Oral HER Pathway Targeted Drugs report makes...0 Maoni 0 Shiriki 12 Mitazamo 0 Hakiki
-
Spindle Cell Sarcoma Drugs Market – Targeted Oncology Therapies & Rare Cancer Treatment Progress"Executive Summary Spindle Cell Sarcoma Drugs Market Opportunities by Size and Share CAGR Value Data Bridge Market Research analyses that the global spindle cell sarcoma drugs market is expected which was USD 27030.00 million 2022 is expected to reach USD 43081.71 million 2030 to undergo a CAGR of 6.00% during the forecast period 2023-2030. The leading Spindle Cell Sarcoma Drugs...0 Maoni 0 Shiriki 321 Mitazamo 0 Hakiki
-
What breakthroughs are propelling the thyroid cancer drug market forward?Executive Summary Thyroid Cancer Drug Market Value, Size, Share and Projections CAGR Value Data Bridge Market Research analyses that the global thyroid cancer drug market which was USD 712.56 million in 2022, is expected to reach USD 2,505.56 million by 2030, and is expected to undergo a CAGR of 17.2% during the forecast period 2023-2030. The world class Thyroid Cancer Drug...0 Maoni 0 Shiriki 336 Mitazamo 0 Hakiki